Musk Plans to Settle with SEC Over X Stock Disclosure Issue, Paving the Way for SpaceX IPO
Svmuu News According to a report from the AXIOS website, based on a court filing from the U.S. Securities and Exchange Commission (SEC), Elon Musk is in settlement negotiations with the SEC regarding his failure to disclose his purchase of Twitter stock before issuing a takeover offer in April 2022. The report states that SpaceX's bankers hope to resolve this matter before potentially launching what could be the largest IPO in history. According to regulations, investors who purchase 5% or more of a publicly traded company's shares must disclose their ownership within 10 days of the purchase. However, Musk disclosed his holdings 21 days after reaching that threshold. He also filed a "13G" form, which is applicable to passive investors, instead of using the "13D" form intended for activist investors, including those planning to make a takeover offer. Musk's lawyers told the court earlier this month that, at least to some extent, these settlement negotiations were conducted without the involvement of the SEC enforcement lawyers handling the case. (Jin10)
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
3
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
4
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
5
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
6
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
7
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
8
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
9
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
10
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
Markets Today
Recommended Reading









